Abstract
Control of cell growth and differentiation has long been a focus of intense research interest, particularly in the context of cancer therapeutics. The evolutionarily-conserved extracellular signal-regulated kinases 1 and 2 (ERK1/2) are serine-threonine kinases that respond to a wide range of mitogens and growth factors to initiate changes in cellular proliferation and differentiation, and are the most important members of the mitogen-activated protein kinase (MAPK) family in terms of seven transmembrane-domain receptor (7TMR)-mediated regulation of mitogenic processes. Regulation of the ERK1/2 signaling cascade by 7TMRs is highly complex and cell type-specific. Recent advances in our knowledge of this effector pathway have revealed that its regulation is at least partly independent of traditional G protein-mediated actions arising from the stimulation of 7TMRs. This review summarizes the current position of our knowledge of ERK1/2 regulation, and illustrates the wealth of potential targets available for the development of new strategies for the treatment of proliferative and other ERK-related disorders.
Keywords: PKC activation, Raf, phosphorylation, gsp oncogene, adrenoceptor, Scaffolding Proteins
Current Pharmaceutical Design
Title: Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Volume: 12 Issue: 14
Author(s): Tim D. Werry, Arthur Christopoulos and Patrick M. Sexton
Affiliation:
Keywords: PKC activation, Raf, phosphorylation, gsp oncogene, adrenoceptor, Scaffolding Proteins
Abstract: Control of cell growth and differentiation has long been a focus of intense research interest, particularly in the context of cancer therapeutics. The evolutionarily-conserved extracellular signal-regulated kinases 1 and 2 (ERK1/2) are serine-threonine kinases that respond to a wide range of mitogens and growth factors to initiate changes in cellular proliferation and differentiation, and are the most important members of the mitogen-activated protein kinase (MAPK) family in terms of seven transmembrane-domain receptor (7TMR)-mediated regulation of mitogenic processes. Regulation of the ERK1/2 signaling cascade by 7TMRs is highly complex and cell type-specific. Recent advances in our knowledge of this effector pathway have revealed that its regulation is at least partly independent of traditional G protein-mediated actions arising from the stimulation of 7TMRs. This review summarizes the current position of our knowledge of ERK1/2 regulation, and illustrates the wealth of potential targets available for the development of new strategies for the treatment of proliferative and other ERK-related disorders.
Export Options
About this article
Cite this article as:
Werry D. Tim, Christopoulos Arthur and Sexton M. Patrick, Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors, Current Pharmaceutical Design 2006; 12 (14) . https://dx.doi.org/10.2174/138161206776873725
DOI https://dx.doi.org/10.2174/138161206776873725 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular microRNAs
Current Drug Targets Anti-inflammatory Property of AMP-activated Protein Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis
Current Vascular Pharmacology Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas
Current Pharmaceutical Design Quantitative Proteomics for Cancer Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Activation of Human Platelets by 2-Arachidonoylglycerol: Role of PKC in NO/cGMP Pathway Modulation
Current Neurovascular Research Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System
Current Pharmaceutical Design Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice
Current Pediatric Reviews Modulators of Inhibitor of Growth (ING) Family Expression in Development and Disease
Current Drug Targets Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Attention Deficit Hyperactivity Disorder and N-methyl-D-aspartate (NMDA) Dysregulation
Current Pharmaceutical Design Editorial [Hot Topic:Angiogenesis Agents(Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design A Comparative Study of Two Novel Nanosized Radiolabeled Analogues of Methionine for SPECT Tumor Imaging
Current Medicinal Chemistry Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine
Anti-Cancer Agents in Medicinal Chemistry <i>In Vitro</i> Effects of Propofol on Cytotoxic, Apoptotic and PI3K-Akt Signaling Pathway Genes on Brain Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics